Sponsors

About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its medicines are used by millions of patients worldwide.

With a proud 100-year heritage in advancing UK science, today AstraZeneca is the UK’s leading biopharmaceutical company. The company is based in five different locations across the UK, with its global headquarters in Cambridge. In the UK, around 8,700 employees work in research and development, manufacturing, supply, sales, and marketing. We supply around 36 different medicines to the NHS.

For additional information please visit: www.astrazeneca.co.uk and follow us on Twitter @AstraZenecaUK

Declaration of Sponsorship. AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia.

Headquartered in Parma, Italy, Chiesi Farmaceutici is an international researchoriented biopharmaceuticals group with over 85 years’ experience in the pharmaceutical sector with 31 affiliates, employing over 7,000 people. Chiesi develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. The Group’s research and development centre in Parma works alongside six other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. Chiesi Limited is headquartered in Manchester and employs over 400 people.

For additional information please visit: www.chiesi.uk.com

Declaration of Sponsorship. CHIESI Sponsorship is made through the purchase of exhibition space and/or sponsored speaker sessions. CHIESI has no o editorial input into or control over the Conference Agenda, content development or choice of speakers, nor opportunity to influence except for the sponsored symposia presentations.

Sanofi Statement
Sanofi is a global pharmaceutical company dedicated to advancing solutions in healthcare. We want to help build a healthier and more resilient world, by discovering, developing and delivering medicines and vaccines. We are committed to working with healthcare professionals, across industry, with the Government and with patient communities to improve people’s lives.
At Sanofi, we work across a broad range of therapy areas, including immunology, oncology, rare diseases, and in Neurology. We want to ensure people living with these conditions are at the centre of what we do – we aim to understand people’s experiences and ensure that is reflected across our work.

PR statement for Regeneron
Regeneron Ltd. We are a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.
Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories.

Sponsorship statement used before
With sincere thanks for sponsorship and continued support from [competitor], [competitor] and Sanofi/Regeneron who have had no influence over the content of the meeting. Providing sponsorship via promotional stands to cover room hire and food during the meeting.

For additional information please visit: Leading Pharmaceutical Innovations | Sanofi UK

Declaration of Sponsorship. SANOFI has provided sponsorship towards this independent Programme and has had no involvement in its creation or organisation.

GSK are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. NP-GB-RS-COCO-230002 | January 2024

For additional information please visit: www.gsk.com/en-gb

Declaration of Sponsorship. This event is sponsored by pharmaceutical and healthcare companies who have contributed funding towards the event in return for exhibition space and/or sponsored speaker sessions. Sponsorship money has been used directly to support the delivery of the event including venue fees and daytime catering. No sponsorship funds have been used to support the evening dinner, nor the poster awards ceremony. Sponsors have had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the sponsored symposia presentations. A full list of conference exhibitors can be found at the following page https://www.copd-uk.com/sponsors

At Roche UK, we focus our energy and investment in developing tests and treatments that change lives and give us more quality time with the people we love. And, together with others, we’re aiming to solve healthcare’s greatest challenges; helping to achieve better results by connecting early diagnosis to targeted treatment and ongoing support.

Healthcare matters to all of us. That’s why we work hard to ensure that all our new medicines are made available to those who need them through the NHS - wherever they live, whatever their circumstances.

In 2023, more than 755 million Roche diagnostic tests were used to confirm, rule out or manage health conditions and over 546,000 patients benefited from our medicines and diabetes monitoring and insulin delivery system. During this period, we contributed £1.56 billion to the UK economy, supporting nearly 20,000 jobs.

Proud of what we do, we’re here because we care. In the UK we employ over 2,000 brilliant specialists who work together to transform the lives of patients and their loved ones.

That’s what makes us who we are. That’s what makes us Roche UK.

For additional information please visit: www.roche.co.uk

Declaration of Sponsorship. Roche Products Ltd has provided financial support for this meeting but has had no involvement in the content.

Fisher & Paykel Healthcare is a global designer, manufacturer and marketer of respiratory products for use in acute and chronic respiratory care, surgery and treatment of obstructive sleep apnea (OSA).

Headquartered in New Zealand, we have for more than 50 years crafted humidification technologies to support individual respiratory needs across the healthcare spectrum. F&P Healthcare and its more than 7000 employees have focused on developing innovative therapies that change clinical practice and help deliver a more sustainable healthcare service the world over. It has worked alongside healthcare professionals, knowing their clinical input is critical to success.

Today, our medical devices are used in the treatment of around 14 million patients in more than 120 countries each year, and the company remains unwavering in its drive to produce medical devices that improve the care, outcomes and quality of life of patients.

For additional information please visit: www.fphcare.com

Global leader in interventional pulmonology, planning tools and treatments for COPD. Headquartered in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is the Zephyr endobronchial valve manufacturer. The FDA approved the Zephyr® valve and granted it breakthrough medical device status in June 2018 because, in its judgment, "it is an innovative technology in offering bronchoscopic lung volume reduction without the need for surgery and associated risks. Compared to the current standard of care, this device offers significant advantages of clinical relevance and therefore its availability is also in the interest of patients."

Among the company's commercially available product range is the Zephyr endobronchial valve. More than 100 scientific articles have been published on the clinical benefits of Zephyr valves, including numerous meta-analyses, review articles, cost-effectiveness analyses, and risk-benefit analyses.

For additional information please visit: pulmonx.com

Resmed is a global pioneer in innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our ecosystem of cloud-connected medical devices help transform care for people with sleep apnoea, and other chronic diseases, while our digital health technologies drive new efficiencies in population health management.

The healthcare environment in the UK is evolving rapidly. As the population ages, chronic diseases are becoming more common. As a result, there is increased pressure on the healthcare industry and providers. Resmed is stepping up to the challenge and creating a future where healthcare is faster, more effective and more efficient. We’re connecting data, connecting patients and connecting healthcare to facilitate care and improve the therapy experience.

With more than 20.5 million cloud-connectable devices worldwide providing medical sleep and respiratory data, we are continuously working to reduce the impact of chronic disease and lower costs for consumers and healthcare systems.

Telemonitoring is particularly appropriate for the management of chronic, progressive conditions that require regular clinical follow-up, such as neuromuscular disease and chronic obstructive pulmonary disease (COPD).

AirView, our cloud-based patient monitoring system, connects to Resmed’s sleep, ventilation and high-flow therapy (HFT) devices so you can manage and support patients on these different treatments via the same platform.

Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.

For additional information please visit: www.resmed.co.uk

For additional information please visit: tidalsense.com

Trudell Medical International are leaders in designing and manufacturing the highest quality aerosol drug delivery and lung health devices for the management of respiratory conditions. Our mission is to help people breathe better and live fuller lives. We achieve this through patient and user centric products, designed and manufactured by a dedicated team of individuals. Our high-quality products are differentiated in the marketplace by their clinical utility, innovation and unique patient-centric design. Many of our products have won design awards and all our products are backed by science and supported with 100+ peer reviewed articles in leading journals and over 300 patents.

For additional information please visit: www.trudellmed.com/uk/en